AYX-401

AYX-401 is an investigational **red blood cell-encapsulated arginase enzyme therapy** being developed by **Ayma Therapeutics** using its ERYCAPS red cell encapsulation platform. The program is intended to deliver arginase activity in a sustained manner by loading the enzyme into transfusion-grade red blood cells, with the goal of **systemically depleting arginine** and thereby addressing **arginase deficiency (argininemia)** and selected **oncology** settings in which arginine depletion may have therapeutic value. Based on company materials, AYX-401 is positioned as a preclinical program and as a potential longer-acting, less-frequently dosed arginine-depleting approach relative to existing arginase-based therapies.

Other names

red cell encapsulated arginasered cell-encapsulated arginasered cell-encapsulated enzyme